These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 27.04.2020 and posted on 28.04.2020by Davia Prischich, Alexandre M. J. Gomila, Santiago Milla-Navarro, Gemma Sangüesa, Rebeca Diez-Alarcia, Beatrice Preda, Carlo Matera, Montserrat Batlle, Laura Ramírez, Ernest Giralt, Jordi Hernando, Eduard Guasch, J. Javier Meana, Pedro de la Villa, Pau Gorostiza
Adrenoceptors are ubiquitous
and regulate heart and respiratory
rate, digestion, metabolism, and vascular tone. They can be activated or
blocked with adrenergic drugs, but systemic administration causes broad adverse
effects. We have developed photochromic ligands (adrenoswitches) to switch on
and off adrenoceptor activity on demand at selected locations. Their pharmacology,
photochromism, bioavailability and lack of toxicity allow photomodulating adrenergic
signalling, as demonstrated by controlling locomotion in zebrafish and pupillary
responses in blind mice.